Abiraterone Acetate (CB7630)

A recent announcement about the once daily oral drug abiraterone acetate (CB7630) indicated that some of the current trial results demonstrate some efficacy in men with hormone refractory prostate cancer. The positive results appeared at two different stages of the standard treatment process. Positive results were demonstrated both before and after the administration of chemotherapy. [...]